Skip to main content
. 2014 Apr;74(4):361–369. doi: 10.1055/s-0033-1360263

Table 2 Therapy data of the PATH patients with follow-up as well as indicators from the WBC bench mark report 2009 and the DMP-reports of the years 2010 (North Rhineland) or, respectively, 2011 (Bavaria).

PATHabsolute and relative frequencies (n = 2 697) PATHrelative frequency referred to the valid answers (yes/no) (95 % CI) Bench mark report WBCnumberrelative frequency (95 % CI) 10 Quality report DMP breast cancer Bavarianumberrelative frequency (95 % CI) 11 Quality report DMP breast cancer North Rhinelandnumberrelative frequency (95 % CI) 12
Special features WBC: planning of hormone therapy evaluated, since the therapy is often carried out at some time after residence in the WBC cooperation clinic.Special features DMP breast cancer: North Rhineland and Bavaria: bisphosphonate therapy in cases with bone metastases. Only North Rhineland: Radiotherapy in cases of BPT already completed at the time of the report.
Breast preserving therapy (BPT) n = 2 684 n = 36 369

  • yes

 2 096 (77.7) 78.1 (76.5; 79.7) 72.0 (71.5; 72.5) – –

  • no

 588 (21.8)

  • not known

 13 (0.5)
T1 tumour and BPT n = 1 723 n = 17 772 n = 3 896 n = 7 496

  • yes

 1 491 (68.3) 86.5 (84.9; 88.1) 85.0 (84.5; 85.5) 88.0 (67.0; 89.0) 82.2 (81.3; 83.1)

  • no

 232 (13.4)

  • not known

 4 (0.2)
T1/T2 tumour and BPT n = 2 504

  • yes

 2 031 (80.8) 81.1 (79.6; 82.6) – – –

  • no

 473 (18.8)

  • not known

 9 (0.4)
Radiotherapy n = 2 473

  • yes

 2 194 (81.3) 88.7 (87.5; 89.9) – – –

  • no

 279 (10.3)

  • not known

 224 (8.3)
Radiotherapy after BPT n = 1 955 n = 21 212 n = 1 070 n = 8 967

  • yes

 1 894 (90.4) 90.4 (89.1; 91.7) 85.0 (84.5; 85.5) 85.0 (82.9; 87.1) 62.0 (61.0; 63.0)

  • no

 61 (2.9)

  • not known

 141 (6.7)
Chemotherapy n = 2 252

  • yes

 1 160 (43.0) 51.5 (49.4, 53.6) – – –

  • no

 1 092 (40.5)

  • not known

 445 (16.5)
Chemotherapy in cases of positive nodes and negative hormone receptors n = 101 n = 6 800 n = 198 n = 684

  • yes

 95 (70.9) 70.9 (62.0; 79.8) 75.0 (74.0; 76.0) 78.0 (72.2; 83.8) 78.1 (75.0; 81.2)

  • no

 6 (4.5)

  • not known

 33 (24.6)
Antihormonal therapy n = 2 427

  • yes

 2 042 (75.7) 75.7 (74.0; 77.4) – – –

  • no

 385 (14.5)

  • not known

 270 (10.0)
Antihormonal therapy with positive hormone receptors n = 2 054 n = 27 956 n = 916 n = 10 328

  • yes

 1 984 (87.5) 87.5 (86.1; 88.9) 97.0 (96.8; 97.2) 91.0 (89.2; 92.9) 69.9 (69.0; 70.8)

  • no

 70 (3.1)

  • not known

 213 (9.4)
Herceptin n = 2 431

  • yes

 254 (9.5) 9.4 (8.2; 10.6) –

  • no

 2 177 (80.7)

  • not known

 266 (9.9)
Herceptin with positive Her2-neu n = 300

  • yes

 225 (68.0) 68.0 (62.7; 73.3) –

  • no

 75 (22.7)

  • not known

 31 (9.4)
Bisphosphonate therapy n = 2 432 n = 164 n = 518

  • yes

 414 (15.4) 17.0 (15.5; 18.5) – 82.0 (76.1; 87.9) 88.8 (86.1; 91.5)

  • no

 2 018 (74.8)

  • not known

 265 (9.8)